MSLN and mesothelioma: As model antibodies, we used two mAbs: anti-MSLN mAb amatuximab (mouse/human chimeric antibody with 82.6% amino acid sequence identity to a human IgG1κ and 10−9 M KD binding affinity), a therapeutic mAb currently investigated in mesothelioma patients, and control anti-Lewis-Y mAb B3 (murine IgG1κ with 10−8 M KD binding affinity).